Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Acasunlimab · 5 trials · 7 indications
Assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
| Arm | Type | Description |
|---|---|---|
| Acasunlimab in Combination with Pembrolizumab | EXPERIMENTAL | Participants with relapsed/refractory, unresectable locally advanced or metastatic cutaneous melanoma that progressed on/after prior CPI(s) will receive acasunlimab once every 6 weeks (Q6W) in combination with pembrolizumab Q6W. |
| Acasunlimab | EXPERIMENTAL | Participants with relapsed/refractory, unresectable locally advanced or metastatic cutaneous melanoma that progressed on/after prior CPI(s) will receive acasunlimab Q6W. |
| Name | Type | Description |
|---|---|---|
| Acasunlimab | DRUG | IV infusion |
| Pembrolizumab | DRUG | IV infusion |
| Docetaxel | DRUG | IV infusion |
| Acasunlimab in combination with docetaxel (in a single expansion cohort) | BIOLOGICAL | Acasunlimab and docetaxel will be administered intravenously once every 21 days. |
| Acasunlimab in combination with pembrolizumab (in a separate expansion cohort) | BIOLOGICAL | Acasunlimab and pembrolizumab will be administered intravenously once every 21 days or every 42 days, respectively. |
| Acasunlimab in combination with pembrolizumab and standard chemotherapy (in separate expansion cohorts) | BIOLOGICAL | Acasunlimab and pembrolizumab and standard chemotherapy will be administered intravenously once every 21 days for 4 cycles, followed by treatment with acasunlimab and pembrolizumab once every 21 days. |
Key Inclusion Criteria: * Participants ≥ 18 years of age with histologically or cytologically confirmed diagnosis of relapsed/refractory, locally advanced unresectable (Stage IIIB, IIIC, or IIID) or metastatic (Stage IV) cutaneous melanoma, per American Joint Committee on Cancer (8th edition) stagi...